Nov 24, 2022

Extending anti-clotting treatment after distal deep vein thrombosis could reduce further clot risk

Posted by in category: biotech/medical

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after treatment, finds a trial published by The BMJ today.

What’s more, the additional six weeks of treatment did not result in increased bleeding risk, a common side effect of anti-clotting drugs.

Rivaroxaban is an anticoagulant drug. It’s given to people at a high risk of getting to help their blood (thicken) more slowly.

Comments are closed.